Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen

American Journal of Managed Care

Volumn 13, Issue 8, 2007, Pages 457-463

  Riedel, Aylin A ^a   Heien, Herbert ^a   Wogen, Jenifer ^b   Plauschinat, Craig A ^c  

^a Ingenix Inc   (United States)

^b MedMentis Consulting LLC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; GLUCOSE HOMEOSTASIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT FAILURE; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT FAILURE; UNITED STATES;

EID: 34548119217     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
2. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932.
3. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care. 2007;30(suppl 1):S4-S41.
4. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
5. Fan T, Koro CE, Fedder DO, Bowlin SJ. Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002. Diabetes Care. 2006;29:1924-1925.
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-1972.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-865.
8. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281: 2005-2012.
9. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-378.
11. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25:213-229.
12. ACE Consensus Development Conference on Guidelines for Glycemic Control. Available at: http://www.aace.com/meetings/consensus/dcc/pdf/ dccwhitepaper.pdf. Accessed July 26, 2007.
13. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48:1093-1104.
14. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167-174.
15. Bell DSH, Ovalle F. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea? Endocr Pract. 2000;6:293-295.
16. Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995-1000.
17. Bell DSH, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab. 2006;8:110-115.
18. Karter AJ, Moffet HH, Liu J, et al. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care. 2005;11:262-270.
19. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5:424-431.
20. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213-217.
21. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
22. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care. 1986;9:129-133.
23. Lopez-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, et al. Acarbose vs bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. Diabetes Obes Metab. 1999;1:29-35.
24. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Treatment escalation and rise in HbA1c following successful initial metformin therapy. Diabetes Care. 2006;29:504-509.
25. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Contemporary analysis of secondary failure of successful sulfonylurea therapy. Endocr Pract. 2007;13:37-44.